1/14/2021 8:15:15 AM
Lexicon Gets FDA Feedback That Results Of SOLOIST, SCORED Phase 3 Studies Can Support NDA Submission
12/31/2020 8:07:54 AM
Lexicon Begins Patient Dosing In RELIEF-PHN 1 Study Of LX9211 For Post-herpetic Neuralgia
12/11/2020 8:10:29 AM
Lexicon Receives Fast Track Designation From FDA For Development Of LX9211
12/11/2020 8:08:46 AM
Lexicon Plans Direct Offering Of 20.31 Mln Shares At $3.20 Per Share
9/4/2020 8:04:19 AM
Lexicon Pharma Begins Patient Dosing In RELIEF-DPN-1 Phase 2 Clinical Study Of LX9211
8/3/2020 7:26:37 AM
TerSera Therapeutics Enters Definitive Agreement To Acquire Product Xermelo From Lexicon
7/21/2020 7:09:23 AM
Lexicon: All Four Phase 3 Sotagliflozin Studies Met Primary Objectives Of Lowering A1C In Patients With Type 2 Diabetes
4/27/2020 7:19:21 AM
Lexicon Q1 Revenues Decrease To $8.0 Mln From $9.2 Mln Last Year
3/12/2020 7:23:19 AM
Lexicon Q4 Loss $51.1 Mln Or $0.48/Shr Vs Loss $16.8 Mln Or $0.16/Shr Year-ago
8/1/2019 10:10:16 AM
Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $17 Down From $35 Price Target